Clinical Trials Logo

Refractory Cancer clinical trials

View clinical trials related to Refractory Cancer.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06372574 Recruiting - Solid Tumor, Adult Clinical Trials

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A*02 eligible patients with locally advanced or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive solid tumors.

NCT ID: NCT06229340 Recruiting - Lung Cancer Clinical Trials

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

N??-RAS
Start date: October 3, 2023
Phase: Phase 2
Study type: Interventional

There is a huge variety of nucleotide substitutions that activate RAS. The search for new "universal" drugs for the RAS pathway that either interfere with RAS upregulation upstream in the signaling pathway or offset the consequences of RAS activation is important for improving therapeutic outcomes for patients with refractory malignancies. The use of leflunomide or the combination of MEK inhibitor + hydroxychloroquine ± bevacizumab is promising for patients with mutations in RAS cascade genes who have failed all existing treatment standards.

NCT ID: NCT06184035 Recruiting - Solid Tumor Clinical Trials

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Tumorad
Start date: November 30, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of [177Lu]Lu-SN201 in adult participants with advanced solid tumors who have no standard of care treatment options. [177Lu]Lu-SN201 is a radiolabeled, nanomedical investigational medicinal product (IMP) whose mechanism of delivery is based on the Enhanced Permeability and Retention (EPR) effect.

NCT ID: NCT06104488 Recruiting - Solid Tumor Clinical Trials

A Study of Avutometinib for People With Solid Tumor Cancers

Start date: October 20, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.

NCT ID: NCT06096038 Recruiting - Clinical trials for Head and Neck Cancer

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Start date: April 5, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen (iC9.CAR-CSPG4 T cells) in patients with head and neck cancer that came back after receiving standard therapy for this cancer. The iC9.CAR-CSPG4 treatment is experimental and has not been approved by the Food and Drug Administration. How many (dose) of the iC9.CAR. CSPG4 T cells are safe to use in patients without causing too many side effects, and what is the maximum dose that could be tolerated will be investigated. The information collected from the study would help cancer patients in the future. There are two parts to this study. In part 1, blood will be collected to prepare the iC9.CAR-CSPG4 T cells. Disease fighting T cells will be isolated and modified to prepare the iC9.CAR-CSPG4 T cells. In part 2, the iC9.CAR-CSPG4 T cells are given by infusion after completion of lymphodepletion chemotherapy. The data from the dose escalation will be used to determine a recommended phase 2 dose (RP2D), which will be decided based on the maximum tolerated dose (MTD). Additionally, recommended phase 2 dose will be tested. Eligible subjects will receive lymphodepletion chemotherapy standard followed by infusion of iC9-CAR.CSPG4 T cells. After treatment completion or discontinuation, subjects will be followed since involving gene transfer experiments.

NCT ID: NCT06024603 Recruiting - Refractory Cancer Clinical Trials

Individualized Treatments in Adults With Relapsed/Refractory Cancers

Start date: November 20, 2023
Phase: N/A
Study type: Interventional

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

NCT ID: NCT05958121 Recruiting - Cancer Clinical Trials

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Start date: August 9, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: - To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) - To characterize the safety and tolerability of IMA402 (Phase I/II) - To evaluate anti-tumor activity of IMA402 (Phase II) Secondary objectives: - To evaluate the initial anti-tumor activity of IMA402 (Phase I) - To evaluate anti-tumor activity of IMA402 (Phase II) - To describe the PK of IMA402 (Phase I/II)

NCT ID: NCT05864144 Recruiting - Breast Cancer Clinical Trials

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Start date: May 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.

NCT ID: NCT05859074 Recruiting - Melanoma Clinical Trials

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Start date: May 4, 2023
Phase: Phase 1
Study type: Interventional

Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

NCT ID: NCT05856981 Recruiting - Solid Tumor, Adult Clinical Trials

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Start date: April 3, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPĪ± monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).